150,000 Shares in PROCEPT BioRobotics Corporation $PRCT Purchased by C WorldWide Group Holding A S

C WorldWide Group Holding A S purchased a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 150,000 shares of the company’s stock, valued at approximately $5,354,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Mitsubishi UFJ Trust & Banking Corp bought a new stake in shares of PROCEPT BioRobotics during the 2nd quarter worth about $5,892,000. Lisanti Capital Growth LLC bought a new position in PROCEPT BioRobotics in the 2nd quarter valued at about $2,532,000. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in PROCEPT BioRobotics by 109.3% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 159,874 shares of the company’s stock worth $9,209,000 after acquiring an additional 83,498 shares during the last quarter. Chicago Capital LLC lifted its position in PROCEPT BioRobotics by 175.7% during the third quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock worth $55,992,000 after acquiring an additional 999,873 shares during the last quarter. Finally, Candriam S.C.A. boosted its holdings in shares of PROCEPT BioRobotics by 104.8% during the second quarter. Candriam S.C.A. now owns 63,125 shares of the company’s stock worth $3,636,000 after acquiring an additional 32,301 shares during the period. Institutional investors own 89.46% of the company’s stock.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $27.40 on Friday. The business has a fifty day moving average price of $32.08 and a two-hundred day moving average price of $36.09. The stock has a market capitalization of $1.53 billion, a PE ratio of -17.91 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20. PROCEPT BioRobotics Corporation has a fifty-two week low of $27.23 and a fifty-two week high of $75.29.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. The company had revenue of $83.33 million for the quarter, compared to analysts’ expectations of $80.78 million. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.PROCEPT BioRobotics’s revenue was up 42.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.40) earnings per share. As a group, equities analysts predict that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PRCT has been the topic of a number of recent research reports. Piper Sandler reiterated an “overweight” rating and set a $50.00 target price (down previously from $55.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. TD Cowen lowered their price objective on PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Bank of America reissued a “neutral” rating and set a $38.00 target price (down previously from $55.00) on shares of PROCEPT BioRobotics in a report on Monday, December 8th. Leerink Partners restated an “outperform” rating and issued a $55.00 price target on shares of PROCEPT BioRobotics in a research note on Wednesday, November 5th. Finally, Truist Financial lowered their price target on shares of PROCEPT BioRobotics from $50.00 to $47.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, PROCEPT BioRobotics presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.40.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.